Drug Trial News

RSS

FibroGen announces presentation of FG-4592 Phase 2 data on anemia at ASN Kidney Week 2012

FibroGen, Inc., today announced that two abstracts relating to FG-4592, its oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) clinical candidate for the treatment of anemia in chronic kidney disease, have been accepted for oral and poster presentations at the American Society of Nephrology (ASN) Kidney Week 2012.

1 Nov 2012

Isis announces preliminary data from ISIS-STAT3 Phase 1 study on cancer

Isis Pharmaceuticals, Inc. announced that preliminary data from the Phase 1 study of ISIS-STAT3Rx in patients with cancer were presented today at the Oligonucleotide Therapeutics Society in Boston.

1 Nov 2012

Additional data from EnVivo’s EVP-6124 Phase 2b trial on AD presented at CTAD meeting

EnVivo Pharmaceuticals, a company dedicated to developing a broad range of novel central nervous system (CNS) therapies, today presented pharmacokinetic and pharmacodynamic data along with the previously reported statistically significant clinical results from its Phase 2b clinical trial of EVP-6124, a novel alpha-7 agonist, in patients with Alzheimer's disease.

1 Nov 2012

AKP America commences ART-123 Phase 3 trial in severe sepsis patients with coagulopathy

Asahi Kasei Pharma America Corp. today announced the initiation of an 800-patient Phase 3 clinical trial for ART-123 (recombinant human thrombomodulin, marketed as Recomodulin in Japan) in severe sepsis patients with coagulopathy.

1 Nov 2012

Orexo initiates OX51 Phase II trial in patients undergoing prostate biopsy

Swedish specialty pharmaceutical company Orexo today communicated the start of the dose finding study for OX51 in patients undergoing prostate biopsy.

31 Oct 2012

Nabilone shows promise in treating diabetic neuropathy

A study from the University of Calgary's Hotchkiss Brain Institute shows there is evidence to support a new drug therapy called nabilone to treat diabetic neuropathy, or nerve pain.

31 Oct 2012

Top-line results from Neuraltus’ NP001 Phase 2 study on amyotrophic lateral sclerosis

Neuraltus Pharmaceuticals, a private biopharmaceutical company developing novel therapies for rare neurological disorders, announced today top-line results from the Company's Phase 2 clinical study of NP001 in patients with Amyotrophic Lateral Sclerosis (ALS, or Lou Gehrig's disease).

30 Oct 2012

Doxepin oral rinse relieves mouth pain from head and neck cancer treatment

30 Oct 2012

TTP488 slows cognitive decline in patients with mild to moderate Alzheimer's

A novel, orally administered drug candidate, TTP488, has demonstrated clinical evidence of slowing of cognitive decline over 18 months of therapy in patients with mild to moderate Alzheimer's disease.

30 Oct 2012

Positive results from Celldex’s CDX-1401 Phase 1 study on solid tumors

Celldex Therapeutics, Inc. today announced positive results demonstrating promising clinical effects in a Phase 1 study of CDX-1401 in solid tumors in combination with the toll-like receptor (TLR) agonists resiquimod and/or Poly ICLC.

30 Oct 2012

Positive interim data from XBiotech monoclonal antibody Phase II study for type 2 diabetes

XBiotech, a privately held biotechnology company, announced positive interim analysis results today from a Phase II study using a True Human monoclonal antibody (MABp1) in patients with type 2 diabetes. Results from this study continue to reinforce the role of IL-1α as a master regulator of chronic inflammation in multiple disease states, and the therapeutic benefits of neutralizing antibodies produced from the XBiotech platform.

29 Oct 2012

Antidepressant doxepin eases pain associated with oral mucositis

An oral rinse of the antidepressant doxepin significantly eased pain associated with oral mucositis in patients receiving radiation therapy for cancers of the head and neck, a study led by Mayo Clinic found. The findings were presented at the American Society for Radiation Oncology annual meeting in Boston.

29 Oct 2012

Par to acquire Handa's ANDA for generic Seroquel XR

Par Pharmaceutical Companies, Inc. today announced that its Par Pharmaceutical, Inc. operating subsidiary has entered into an exclusive acquisition and license agreement with Handa Pharmaceuticals, LLC to acquire Handa's Abbreviated New Drug Application (ANDA) for quetiapine fumarate extended-release tablets, the generic version of AstraZeneca's Seroquel XR.

29 Oct 2012

Isis commences ISIS-FXIRx Phase 2 study in knee replacement surgery patients

Isis Pharmaceuticals, Inc. announced the initiation of a Phase 2 comparator-controlled study evaluating ISIS-FXIRx in patients undergoing knee replacement surgery, also referred to as total knee arthroplasty (TKA).

29 Oct 2012

AstraZeneca commences FASLODEX Phase III study for hormone receptor-positive metastatic breast cancer

AstraZeneca today announced the start of a Phase III study (FALCON), a global clinical trial which will involve 450 postmenopausal patients with hormone receptor-positive locally advanced or metastatic breast cancer who have not previously been treated with any hormonal therapy. The Phase III study is designed to evaluate the efficacy and tolerability of fulvestrant 500 mg compared to anastrozole 1 mg in this patient population.

29 Oct 2012

Nonclinical data on Provectus PV-10 oncology drug presented at 27th SITC

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, presented nonclinical data on PV-10 at the Society for Immunotherapy of Cancer (SITC) 27th Annual Meeting on October 26 and 27, 2012 in North Bethesda, MD.

29 Oct 2012

GTx to continue enobosarm Phase III trials for muscle wasting in patients with NSCLC

GTx, Inc. today announced that a per protocol interim safety review on Friday, October 26, 2012, by an independent Data Safety Monitoring Board (DSMB) recommended that GTx continue clinical development as planned with its two pivotal Phase III trials of enobosarm (GTx-024) for the prevention and treatment of muscle wasting in patients with non-small cell lung cancer.

29 Oct 2012

Intracoronary and IV abciximab during angioplasty do not result in differences in myocardial damage

A study confirmed no differences in various measures of heart damage, according to cardiac magnetic resonance (MRI) imaging, in patients receiving the anti-clotting medication abxicimab directly into the heart (intracoronary) compared to those receiving it intravenously (IV).

26 Oct 2012

Journal of Pediatrics assesses issues surrounding lack of clinical drug trials for neonates

Clinical drug trials are a vital part of pharmaceutical manufacturers gaining approval for use by the U.S. Food and Drug Administration. A Commentary scheduled for publication in The Journal of Pediatrics assesses the issues surrounding the lack of clinical trials on medications used by children, most notably neonates, and how drug manufacturers and academic researchers could work together to create clinical trials that would benefit this underrepresented population.

26 Oct 2012

Resveratrol does not appear to offer metabolic benefits in healthy women

Resveratrol, an ingredient in red wine thought to improve insulin sensitivity, reduce risk of heart disease and increase longevity, does not appear to offer these benefits in healthy women, new research at Washington University School of Medicine in St. Louis indicates.

26 Oct 2012

Drug Trial News

FibroGen announces presentation of FG-4592 Phase 2 data on anemia at ASN Kidney Week 2012

Isis announces preliminary data from ISIS-STAT3 Phase 1 study on cancer

Additional data from EnVivo’s EVP-6124 Phase 2b trial on AD presented at CTAD meeting

AKP America commences ART-123 Phase 3 trial in severe sepsis patients with coagulopathy

Orexo initiates OX51 Phase II trial in patients undergoing prostate biopsy

Nabilone shows promise in treating diabetic neuropathy

Top-line results from Neuraltus’ NP001 Phase 2 study on amyotrophic lateral sclerosis

Doxepin oral rinse relieves mouth pain from head and neck cancer treatment

TTP488 slows cognitive decline in patients with mild to moderate Alzheimer's

Positive results from Celldex’s CDX-1401 Phase 1 study on solid tumors

Positive interim data from XBiotech monoclonal antibody Phase II study for type 2 diabetes

Antidepressant doxepin eases pain associated with oral mucositis

Par to acquire Handa's ANDA for generic Seroquel XR

Isis commences ISIS-FXIRx Phase 2 study in knee replacement surgery patients

AstraZeneca commences FASLODEX Phase III study for hormone receptor-positive metastatic breast cancer

Nonclinical data on Provectus PV-10 oncology drug presented at 27th SITC

GTx to continue enobosarm Phase III trials for muscle wasting in patients with NSCLC

Intracoronary and IV abciximab during angioplasty do not result in differences in myocardial damage

Journal of Pediatrics assesses issues surrounding lack of clinical drug trials for neonates

Resveratrol does not appear to offer metabolic benefits in healthy women

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News